• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2023 Fiscal Year Final Research Report

Protection and organ injury by angiotensin II treatment for septic shock

Research Project

  • PDF
Project/Area Number 20K09284
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 55060:Emergency medicine-related
Research InstitutionThe University of Tokyo

Principal Investigator

DOI KENT  東京大学, 医学部附属病院, 教授 (80505892)

Project Period (FY) 2020-04-01 – 2024-03-31
Keywords敗血症
Outline of Final Research Achievements

Septic shock is considered as vasodilatory shock and can be ameliorated by angiotensin II, which is a strong vasoconstrictor. On the other hand, angiotensin II can induce cardiac hypertrophy and renal glomerulosclerosis. The aim of this study was to evaluate the protective effects of angiotensin II against septic shock and possible harm on organ damage in the heart and kidneys. Administration of angiotensin II to mice in a cecal ligation and puncture peritonitis model of septic shock did not improve survival, although we use the doses that reported in the literature to induce a sufficient increase in blood pressure. Not only the dose but also the timing of administration was examined, however the therapeutic effect of angiotensin II could not be confirmed.

Free Research Field

集中治療医学

Academic Significance and Societal Importance of the Research Achievements

敗血症は高い死亡率を呈する病態であり、日本国内でも敗血症で年間約10万人が死亡していると考えられている。敗血症の中でも循環不全を呈する敗血症性ショックの死亡率はさらに高く、早期の抗菌薬投与、十分な輸液蘇生に加えて、血液分布異常性ショックに分類されることから、異常な血管拡張に対する血管収縮薬の投与は必要不可欠とされている。これまでノルアドレナリンやバソプレシンなどが臨床的に広く用いられてきたが、さらなる予後改善を目指すのであれば、新たな作用機序の血管収縮薬が有用であると考えられる。本研究ではアンジオテンシンIIの有効性が示されなかったが、さらなる検討が必要だと考えられた。

URL: 

Published: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi